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Abstract
Background: The response to neoadjuvant chemotherapy has been proven to predict long-term clinical benefits
for patients. Our research is to construct a nomogram to predict pathological complete response of human
epidermal growth factor receptor 2 negative breast cancer patients.
Methods: We enrolled 815 patients who received neoadjuvant chemotherapy from 2003 to 2015 and divided them
into a training set and a validation set. Univariate logistic regression was performed to screen for predictors and
construct the nomogram; multivariate logistic regression was performed to identify independent predictors.
Results: After performing the univariate logistic regression analysis in the training set, tumor size, hormone
receptor status, regimens of neoadjuvant chemotherapy and cycles of neoadjuvant chemotherapy were the final
predictors for the construction of the nomogram. The multivariate logistic regression analysis demonstrated that T4
status, hormone receptor status and receiving regimen of paclitaxel and carboplatin were independent predictors
of pathological complete response. The area under the receiver operating characteristic curve of the training set
and the validation set was 0.779 and 0.701, respectively.
Conclusions: We constructed and validated a nomogram to predict pathological complete response in human
epidermal growth factor receptor 2 negative breast cancer patients. We also identified tumor size, hormone
receptor status and paclitaxel and carboplatin regimen as independent predictors of pathological complete
response.
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Background
Breast cancer is the most common malignant disease
and the second most common cause of cancer death in
women [1]. Neoadjuvant chemotherapy has several
advantages compared with adjuvant chemotherapy [2]. It
increases the rate of breast conservation and offers the
opportunity for patients with locally advanced breast
cancer to receive surgery. Moreover, sensitivity to
different chemotherapy regimens can be assessed, thus
helping to make decisions for subsequent treatment.
Pathological complete response (pCR) has been con-
firmed to predict long-term clinical benefit for patients
receiving neoadjuvant chemotherapy and can serve as a
dependable endpoint when investigating the efficiency of
different treatment regimens [3]. With the application of
human epidermal growth factor receptor 2 blockade
using neoadjuvant treatments such as trastuzumab, per-
tuzumab and lapatinib in human epidermal growth fac-
tor receptor 2 (HER2) positive patients, the pCR rate of
HER2 positive patients is high (16.8–66.2 %) [4]. How-
ever, the pCR rate of HER2 negative patients is relatively
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low (7.0–16.2 % for hormone receptor positive, HER2
negative patients and 33.6–35.0 % for triple negative pa-
tients) [3, 5]. Thus, predicting the response to neoadjuvant
chemotherapy for HER2 negative patients is essential to
optimizing the treatment for individual patients.
Anthracyclines used to be the most common chemo-
therapeutic agents for breast cancer [6]. However, as
taxane-based [7] or platinum-based [8, 9] regimens
showed their advantages, the use of anthracyclines has
been declining in recent years [10]. The potential impact
of this change is still unknown.
A nomogram is a simple graphical representation of a
prediction model that helps oncologists assess the pre-
dictive information of individual patients [11]. Several
earlier studies constructed nomograms to illustrate the
impact of different variables on pCR probability [12–14],
but none of them focused on HER2 negative patients
and different neoadjuvant chemotherapy regimens.
Our current study aims to construct and validate a
well-fitting nomogram based on multivariate logistic re-
gression to evaluate the impact of different neoadjuvant
chemotherapy regimens as well as the impact of several
other variables on the pCR rate among HER2 negative
patients in a prospective cohort.
Methods
Patient population
Relevant clinical data (age, menopausal status, tumor size,
nodal status, regimens of chemotherapy and cycles of
chemotherapy), core needle biopsy samples and surgical
specimens were collected from Fudan University Shanghai
Cancer Center between January 1, 2003 and April 31, 2015.
Overall, 1244 patients who were diagnosed with primary
breast cancer and who received neoadjuvant chemother-
apy followed by standard surgery were enrolled.
Patients with HER2 positive core needle biopsy sam-
ples, with metastatic disease, with missing data or with
previous endocrine therapy were not eligible for this
study. In total, 429 patients who had missing relevant in-
formation, who were HER2 positive or who had received
neoadjuvant chemotherapy regimens other than cy-
clophosphamide, epirubicin and 5-fluorouracil, cyclo-
phosphamide, epirubicin and 5-fluorouracil followed by
paclitaxel or docetaxel and epirubicin, navelbine and
epirubicin or paclitaxel and carboplatin or paclitaxel and
cisplatin were excluded from our study.
The remaining 815 patients were randomized into a
training set (N = 500, enrolled in the nomogram con-
struction) or a validation set (N = 315, enrolled in the
nomogram external validation) (Fig. 1).
Pathology and treatment
Estrogen receptor, progestogen receptor status and
HER2 status were determined by immunohistochemical
analysis, which was performed with formalin-fixed,
paraffin-embedded tissue sections using standard proto-
cols for core needle biopsy specimens by the pathology
department of Fudan University Shanghai Cancer Cen-
ter. The cut-off value for estrogen receptor positivity
and progestogen receptor positivity was set at 1 %. Ab-
sence of both estrogen receptor and progestogen recep-
tor was defined as hormone receptor negative (estrogen
receptor negative and progestogen receptor negative);
presence of either was defined as hormone receptor
positive (estrogen receptor positive or progestogen re-
ceptor positive). HER2-positivity was defined as 3 (+) by
immunohistochemical or amplification and was con-
firmed by fluorescence in situ hybridization. Each speci-
men was examined independently by two experienced
pathologists.
The patients in our cohort received one of the follow-
ing neoadjuvant chemotherapy regimens for a median of
4 cycles (range, 1–6 cycles): navelbine and epirubicin,
cyclophosphamide, epirubicin and 5-fluorouracil, paclitaxel
with carboplatin/paclitaxel with cisplatin or epirubicin and
Fig. 1 Flow diagram of the study design. A total of 815 Human
Epidermal Growth Factor Receptor 2 (HER2) negative patients who
received neoadjuvant chemotherapy with the regimen of
cyclophosphamide, epirubicin and 5-fluorouracil; cyclophosphamide,
epirubicin and 5-fluorouracil followed by paclitaxel or docetaxel and
epirubicin; navelbine and epirubicin; or paclitaxel and carboplatin or
paclitaxel and cisplatin were included in this study
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5-fluorouracil followed by paclitaxel or docetaxel and
epirubicin. pCR was defined as complete disappearance of
invasive carcinoma in the breast and regional lymph
nodes [3].
Construction of the nomogram
To develop a well-calibrated and useful nomogram for
predicting pCR, possible predictive variables were identi-
fied by univariate logistic regression (P < 0.05 in univari-
ate logistic regression analysis). The Hosmer-Lemeshow
test was used to assess the fitness of the nomogram (P >
0.05 indicating good fit) [15]. Multivariate logistic re-
gression analysis was performed to screen independent
variables predicting pCR. Odds ratios and 95 % confi-
dence intervals (CI) were calculated.
Evaluating model performance
The internal validation of our model was performed by a
calibration method and the area under the receiver oper-
ating characteristic (ROC) curve (AUC). Calibration [16]
(visualized as the calibration plot) with a bootstrapping
method [17] was used to illustrate the association be-
tween the actual probability and the predicted probabil-
ity. The external validation was achieved by performing
the ROC as well as the AUC in a separated population.
The AUC ranged from 0 to 1, with the value of 1 indi-
cating perfect concordance, 0.5 indicating no better than
chance, and 0 indicating discordance. Statistical differ-
ences between different AUCs were investigated by the
DeLong method [18].
Statistical analysis
Chi-square test was used to evaluate the relationship be-
tween neoadjuvant chemotherapy regimens and other
characteristics. Fisher’s exact test was performed when
necessary. All reported P-values are two-sided. The stat-
istical analysis was carried out using SPSS (version 20.0;
SPSS Company, Chicago, IL) and R software version 3.13
(http://www.r-project.org). The R package with rms,
pROC, Hmisc and ggplot2 (available at URL: http://cran.r-
project.org/web/packages/) was used (last accessed on




Of the 815 HER2 negative patients enrolled in this study,
111 (13.6 %) reached pCR (Table 1). Young patients
(≤40 years) [19] had higher pCR rates than older patients
(>40 years) (17.0 % versus 12.8 %). Pre-menopausal pa-
tients (14.2 %) had higher pCR rates than those who
were post-menopausal (12.8 %). Patients with smaller
tumor size and more positive lymph nodes reached pCR
more easily. hormone receptor negative patients (23.0 %)
had higher pCR rates than hormone receptor positive
ones (9.8 %). Patients who received the paclitaxel with
carboplatin/paclitaxel with cisplatin regimen had higher
pCR rates than those who received the cyclophospha-
mide, epirubicin and 5-fluorouracil, epirubicin and 5-
fluorouracil followed by paclitaxel or docetaxel and
epirubicin or navelbine and epirubicin regimens (19.4 %
versus 1.9 %, 7.8 and 9.8 %, respectively). Patients
who received 3 to 4 cycles of neoadjuvant chemother-
apy had higher pCR rates (16.1 %) than other sub-
jects. These results were similar in the training and
validation sets.
Predictors for pCR
In the training set, univariate logistic regression was
performed to analyze the association between response
to chemotherapy and patient age, menopausal status,
tumor size, nodal status, hormone receptor status, regi-
mens of chemotherapy and cycles of chemotherapy
(Table 2). Tumor size (P = 0.029), hormone receptor
status (<0.001), and neoadjuvant chemotherapy regi-
mens (P < 0.001) and cycles (P = 0.029) were identified
to be statistically significant predictors of pCR. No
significant differences in pCR rate were observed among
patients with different ages, menopausal statuses or nodal
statuses.
Given that the baseline patient characteristics of differ-
ent neoadjuvant chemotherapy regimens were not in
concordance (Additional file 2), we performed multivari-
ate logistic regression analysis to screen for the inde-
pendent predictors of pCR (Table 3). Relative to T1
patients, T4 patients were less likely to achieve pCR
[P = 0.015, odds ratio =0.281 (95 % CI: 0.101–0779)]. The
odds ratio of hormone receptor positive patients was 0.224
(95 % CI: 0.125–0.400); for hormone receptor negative pa-
tients, it was 1 (P < 0.001). After adjustment for tumor size,
hormone receptor status and neoadjuvant chemotherapy
cycles, those who received paclitaxel with carboplatin/pac-
litaxel with cisplatin had a statistically significant higher
rate of pCR Compared with patients who received cyclo-
phosphamide, epirubicin and 5-fluorouracil [P = 0.003,
odds ratio =27.696 (95 % CI: 3.131–245.030)]. Patients
who received epirubicin and 5-fluorouracil followed by
paclitaxel or docetaxel and epirubicin, navelbine and epiru-
bicin had higher odds ratio than those who received cyclo-
phosphamide, epirubicin and 5-fluorouracil (6.973 and
4.701 versus 1), but the difference was not statistically sig-
nificant. Although we found out the trends that patients
receiving only 1–2 cycles neoadjuvant chemotherapy
showed lower probability for pCR (odds ratio: 0.579) while
patients receiving 5–6 cycles neoadjuvant chemotherapy
showed higher probability for pCR (odds ratio: 2.338)
than those who received 3–4 cycles of neoadjuvant
chemotherapy, different neoadjuvant chemotherapy
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cycles were not statistically significant for predicting
pCR.
We performed logistic regression to explore the pre-
dictors for pCR separately both in hormone receptor
positive and negative cohort. Tumor status (T3 vs T1,
T4 vs T1) was only statistically significant in hormone
receptor positive patients and not in hormone receptor
negative patients. Nodal status was not statistically sig-
nificant in either group. Epirubicin and 5-fluorouracil
followed by paclitaxel or docetaxel with epirubicin and
navelbine with epirubicin showed statistically significant
superiority to cyclophosphamide, epirubicin and 5-
fluorouracil regimens in hormone receptor negative pa-
tients, but not in hormone receptor positive patients,
while paclitaxel with carboplatin/paclitaxel with cisplatin
regimen treated patients had statistically significant
higher pCR in overall patients. Only hormone receptor
negative patients who received 1–2 cycles had statisti-
cally significant lower pCR rate than those receiving 3–4
cycles (Additional file 3). In addition, we found that
Table 1 Clinicopathologic characteristics of patients
Overall Training set Validation set
ALL (N) pCR (N) pCR rate ALL (N) pCR (N) pCR rate ALL (N) pCR (N) pCR rate
Total 815 111 13.6 % 500 68 13.6 % 315 43 13.7 %
Age
≤40 years 165 28 17.0 % 105 17 16.2 % 60 11 18.3 %
>40 years 650 83 12.8 % 395 51 12.9 % 255 32 12.5 %
Menopausal status
Pre-menopausal 457 65 14.2 % 276 40 14.5 % 181 25 13.8 %
Post-menopausal 358 46 12.8 % 224 28 12.5 % 134 18 13.4 %
Tumor size
T1 89 21 23.6 % 60 15 25.0 % 29 6 20.7 %
T2 346 47 13.6 % 210 30 14.3 % 136 17 12.5 %
T3 235 28 11.9 % 137 15 10.9 % 98 13 13.3 %
T4 145 15 10.3 % 93 8 8.6 % 52 7 13.5 %
Nodal status
N0 170 22 12.9 % 100 15 15.0 % 70 7 10.0 %
N1 593 79 13.3 % 363 45 12.4 % 230 34 14.8 %
N2 23 4 17.4 % 16 3 18.8 % 7 1 14.3 %
N3 29 6 20.7 % 21 5 23.8 % 8 1 12.5 %
Hormone receptor status
Negative 235 54 23.0 % 147 36 24.5 % 88 18 20.5 %





107 2 1.9 % 66 1 1.5 % 41 1 2.4 %
Cyclophosphamide,
epirubicin and 5-fluorouracil
followed by paclitaxel or
docetaxel and epirubicin
116 9 7.8 % 73 5 6.8 % 43 4 9.3 %
Navelbine and epirubicin 153 15 9.8 % 94 8 8.5 % 59 7 11.9 %
Paclitaxel and carboplatin
or paclitaxel and cisplatin
439 85 19.4 % 267 54 20.2 % 172 31 18.0 %
Cycles
1-2 97 3 3.1 % 61 2 3.3 % 36 1 2.8 %
3-4 578 93 16.1 % 359 58 16.2 % 219 35 16.0 %
5-6 140 15 10.7 % 80 8 10.0 % 60 7 11.7 %
Abbreviations: pCR pathological complete response
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among paclitaxel with carboplatin/paclitaxel with cis-
platin treated patients, hormone receptor negative (triple
negative) patients had higher rate of pCR rate (38.9 %,
Chi-square test P < 0.001) than hormone receptor posi-
tive patients (13.0 %) (Additional file 4).
Construction and validation of the nomogram
Statistically significant predictors in univariate logistic
regression analysis (tumor size, hormone receptor status,
neoadjuvant chemotherapy regimens and cycles) were
included into the nomogram construction (Fig. 2). The
total points were added up by the points of each variable
(top scale). The pCR probability depended on the total
points (bottom scale). The P-value for the Hosmer-
Lemeshow test was 0.817, indicating good fit of the
model.
The calibration of the nomogram was performed
internally by a calibration plot with bootstrap sampling
(n = 1000) (Fig. 3). The calibration plot illustrated that
the nomogram was well calibrated.
Next, we constructed the ROC to further validate the
nomogram internally in the training set (Fig. 4a) and ex-
ternally in the validation set (Fig. 4b). In the training set,
the AUC was 0.779 (95 % CI: 0.718–0.839). In the valid-
ation set, the AUC was slightly lower: 0.703 (95 % CI:
0.624–0.782). The difference between two AUCs was not
statistical significant (P = 0.132). These results illustrated
that the predicted and observed pCR probabilities were
concordant.
Nomogram performance in individual patients
To display the application of the nomogram, we took two
breast cancer patients who had received neoadjuvant
chemotherapy as examples. The first patient was to re-
ceive epirubicin and 5-fluorouracil followed by paclitaxel
Table 3 Multivariable logistic regression analysis of possible
variables (P<0.05 in univariate logistic regression analysis)
predicting pCR
P OR 95 % CI
Tumor size
T1 1
T2 0.186 0.576 0.255-1.304
T3 0.544 0.737 0.275-1.975
T4 0.015 0.281 0.101-0.779
Hormone receptor status
Negative 1






and 5-fluorouracil followed by
paclitaxel or docetaxel and
epirubicin
0.208 4.673 0.423-51.590
Navelbine and epirubicin 0.078 6.999 0.804-60.897





1-2 0.500 0.579 0.118-2.834
5-6 0.217 2.338 0.606-9.017
Abbreviations: pCR pathological complete response, OR odds ratio, CI
confidence interval
Table 2 Univariate logistic regression analysis of different
variables predicting pCR in the training set




>40 years 0.385 0.767 0.423-1.394
Menopausal status 0.518
Pre-menopausal 1
Post-menopausal 0.518 0.843 0.502-1.416
Tumor Size 0.029
T1 1
T2 0.052 0.500 0.248-1.007
T3 0.014 0.369 0.167-0.815
T4 0.008 0.282 0.111-0.716
Nodal status 0.432
N0 1
N1 0.493 0.802 0.426-1.508
N2 0.701 1.308 0.332-5.147
N3 0.328 1.171 0.564-5.561
Hormone receptor status <0.001
Negative 1






and 5-fluorouracil followed by
paclitaxel or docetaxel and
epirubicin
0.158 4.779 0.544-42.018
Navelbine and epirubicin 0.094 6.047 0.738-49.558
Paclitaxel and carboplatin




1-2 0.018 0.176 0.042-0.740
5-6 0.143 0.577 0.264-1.261
Abbreviations: pCR pathological complete response, OR odds ratio, CI
confidence interval
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or docetaxel and epirubicin as an neoadjuvant chemother-
apy regimen (45 points) for four cycles (19 points); his
tumor size was T2 (22 points) and his hormone receptor
status was positive (0 points). According to the nomo-
gram, his probability of reaching pCR was approximately
0.01 to 0.05 (total points: 86). The second patient was to
receive paclitaxel with carboplatin/paclitaxel with cisplatin
as an neoadjuvant chemotherapy regimen (100 points) for
four cycles (19 points); his tumor size was T4 (0 points)
and his hormone receptor status was negative (50 points).
According to the nomogram, his probability of reaching
pCR was approximately 0.2 to 0.3 (total points: 169). As a
result of using this nomogram, clinicians can obtain an
overview of the response of different treatments for indi-
vidual patients.
Discussion
Based on the logistic regression, we screened for predic-
tors and constructed a concise and well fitted nomogram
containing the variables of tumor size, hormone receptor
status, regimens of neoadjuvant chemotherapy and cy-
cles of neoadjuvant chemotherapy to predict the pCR
rate of HER2 negative patients. This would be a conveni-
ent application for clinicians. Using the method of cali-
bration plot with bootstrap sampling, as well as internal
and external validation by AUC and ROC, the nomo-
gram proved to be of good fitness.
In this study, we first screened variables that could
predict the response to neoadjuvant chemotherapy by
univariate logistic regression. Tumor size, hormone re-
ceptor status, and neoadjuvant chemotherapy regimens
and cycles were included in the construction of the
nomogram. Next, we intended to identify several inde-
pendent predictors of the pCR rate. In the multivariate
logistic regression analysis, we found that T4 status (P =
0.015, odds ratio: 0.281, 95 % CI: 0.101–0.779), hormone
receptor positivity (P < 0.001, odds ratio: 0.224, 95 % CI:
0.125–0.400) and receiving the paclitaxel with carbopla-
tin/paclitaxel with cisplatin regimen (P = 0.003, odds ra-
tio: 27.696, 95 % CI: 3.131–245.030) were the most
important predictors of pCR in this model. Compared
with T1 patients, T4 patients had worse responses to
chemotherapy, which is consistent with previous re-
search [20]. Hormone receptor status was another
independent predictor, and hormone receptor positive
patients had lower pCR rates than hormone receptor
negative patients. Our findings are concordant with
Fig. 2 Nomogram predicting the probability of pathological complete response (pCR) after neoadjuvant chemotherapywith the regimen of
cyclophosphamide, epirubicin and 5-fluorouracil; cyclophosphamide, epirubicin and 5-fluorouracil followed by paclitaxel or docetaxel and
epirubicin; navelbine and epirubicin; or paclitaxel and carboplatin or paclitaxel and cisplatin
Fig. 3 Calibration plot of the nomogram for the probability of
pathological complete response (pCR) (bootstrap 1000 repetitions)
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previous studies [20–22] that show that hormone recep-
tor positive tumor cells are less sensitive to chemother-
apy compared with hormone receptor negative cells.
Patients treated with paclitaxel with carboplatin/paclitaxel
with cisplatin had better neoadjuvant chemotherapy re-
sponses compared with those treated with cyclophospha-
mide, epirubicin and 5-fluorouracil. Anthracyclines such
as epirubicin and doxorubicin were once considered to be
the most effective agents in the treatment of breast cancer,
but the use of them has been declining recently [10]. In
our current study, the anthracycline-based regimens in-
cluded cyclophosphamide, epirubicin and 5-fluorouracil,
epirubicin and 5-fluorouracil followed by paclitaxel or
docetaxel with epirubicin and navelbine with epirubicin.
Cyclophosphamide, epirubicin and 5-fluorouracil was the
standard anthracycline-based regimen, and the pCR rate
after 6 cycles of cyclophosphamide, epirubicin and 5-
fluorouracil was reported to be 14–15 % [23, 24].
However, only 1.9 % of patients who received cyclophos-
phamide, epirubicin and 5-fluorouracil in our study
reached pCR, which may be partially due to the relatively
higher proportion of larger tumor size (T3: 50.5 %; T4:
13.1 %) and fewer neoadjuvant chemotherapy cycles re-
ceived (1–2 cycles: 49.5 %) in the cyclophosphamide, epir-
ubicin and 5-fluorouracil cohort. The total pCR rate for
epirubicin and 5-fluorouracil followed by paclitaxel or do-
cetaxel and epirubicin patients was low (7.8 %) which may
due to the relatively higher proportion of hormone recep-
tor positive patients (87.1 %). The cumulative cardiac tox-
icity of anthracyclines has also limited its use, especially in
older patients or in those with cardiovascular comorbidi-
ties. Therefore, non-anthracycline based regimens are re-
quired. Paclitaxel, a mitotic inhibitor and anti-microtubule
agent, results in a G2-M phase arrest [25]. Carboplatin
and cisplatin share similar anti-cancer mechanisms, as
they are both DNA alkylating agents [26]. The combin-
ation of paclitaxel and platinum is now widely used in
breast cancer patients, and the agents have no overlapping
toxicities [27]. Previous research has already assessed the
efficacy and the toxicity of the paclitaxel with carboplatin/
paclitaxel with cisplatin regimen in adjuvant therapy and
in neoadjuvant chemotherapy. The pCR rate of patients
who received paclitaxel with carboplatin/paclitaxel with
cisplatin as neoadjuvant chemotherapy ranged from 9.5 to
19.4 % [28, 29]. The data from our center is 19.4 %, similar
to previous studies. The paclitaxel with carboplatin/pacli-
taxel with cisplatin regimen achieved greater therapeutic
effect than any anthracycline-based regimens, especially in
triple negative breast cancer patients. Triple negative
breast cancer patients have higher rate of BRCA1/2
(Breast Cancer 1/2) mutation and are sensitive to plat-
inum (because of the deficiencies in the DNA repair
mechanism) [30, 31]. In aggregate, these results suggested
that platinum contained therapy is recommend for triple
negative breast cancer patients.
The nomogram provides a simple graphical represen-
tation of sophisticated statistical prediction models and
has been accepted as a reliable tool for predicting clin-
ical events. It is especially widely used in oncology [11].
Previously, several studies constructed nomograms to
predict the pCR rate of neoadjuvant chemotherapy. The
first of these studies appeared in 2005 [12]. Rouzier et al.
constructed two nomograms to predict the responses to
anthracycline-based neoadjuvant chemotherapy and to
combined anthracycline and paclitaxel neoadjuvant
chemotherapy. The nomograms were validated exter-
nally. Colleoni et al. constructed a nomogram to predict
pCR probability based on a population of 783 patients
[13]. The nomogram proved to be well fitted after exter-
nal validation by 101 patients. However, the HER2 status
was not mentioned in these two studies. Keam et al.
constructed another nomogram to predict pCR and pre-
dict which patients would not relapse [14]. Overall, 370
patients who received 3 cycles of neoadjuvant docetaxel
Fig. 4 Validation of the Nomogram. a Internal validation using receiver operating characteristic (ROC) curve. The area under the ROC curve (AUC)
is 0.779, 95 % confidence intervals (CI): 0.718–0.839. b External validation using ROC. The AUC is 0.703, 95 % CI: 0.622–0.780
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or doxorubicin were included in this study. However, the
HER2 status was not stratified and the validation of the
nomogram was only performed internally. The advan-
tage of our research is that we first constructed a nomo-
gram for predicting the pCR rate among HER2 negative
patients, and the nomogram was proven to be well fitted
by internal and external validation. We selected HER2
negative patients as our target population for two rea-
sons. First, the pCR rates of these patients were relatively
low, so individualized therapy for each patient was re-
quired. Second, confounding variables such as HER2
blockade treatment were limited in our cohort. Add-
itionally, we discovered that paclitaxel with carboplatin/
paclitaxel with cisplatin was the more favored neoadju-
vant chemotherapy regimen compared with cyclophos-
phamide, epirubicin and 5-fluorouracil in HER2 negative
patients.
One limitation of our study was that the design was a
single center analysis. Applying the nomogram in an-
other database will greatly improve the power of our
current result, and we have carefully searched through
existing public databases. Unfortunately, we were unable
to find a proper database containing all of the variables
analyzed in our current study (age, menopause status,
tumor size, nodal status, hormone receptor status, neoad-
juvant chemotherapy regimens, neoadjuvant chemother-
apy cycles and response to neoadjuvant chemotherapy).
We expect to assess the nomogram with large-scale ran-
domized prospective clinical trials. The efficacy and safety
of the paclitaxel with carboplatin/paclitaxel with cisplatin
regimen used in neoadjuvant chemotherapy also needs to
be assessed. Another limitation was that the molecular
mechanisms of the paclitaxel with carboplatin/paclitaxel
with cisplatin regimen (more so than the cyclophospha-
mide, epirubicin and 5-fluorouracil regimen) were unclear
so further research is required in the future to study these
mechanisms.
Conclusion
Our current study screened for several predictors and
constructed a well fitted nomogram based on those pre-
dictors to predict the pCR rate among HER2 negative
breast cancer patients.
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